Increased expression of membrane type 1 matrix metalloproteinase and matrix metalloproteinase-2 with tumor dedifferentiation in hepatocellular carcinomas

Riko Ogata(Kurume University), Kyuichi Tanikawa(Kurume University), Takuji Torimura(Omuta hospital), Yukio Tateishi(Kurume University), Masaharu Sakamoto(Kurume University), M Sata(Kurume University), Yoshihiro Shimauchi(Kurume University), Takato Ueno(Kurume University), S. Tamaki(Kurume University), Ryoko Kuromatsu(Kurume University), Motoaki Kin(Kurume University)
Human Pathology
April 1, 1999
10.1016/s0046-8177(99)90121-1
Cited by 48

Related Papers

Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
|Gut|2019|732
Therapeutic effects of restricted diet and exercise in obese patients with fatty liver
|Journal of Hepatology|1997|614
Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH‐HCC guidelines) 2019 update
|Hepatology Research|2019|539
Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review
|Journal of Hepatology|2016|504
MAFLD identifies patients with significant hepatic fibrosis better than NAFLD
|Liver International|2020|410